Predictive molecular signatures for successful tapering of canakinumab in systemic juvenile idiopathic arthritis
Authors' conclusion
Serum inflammatory markers and targeted gene expression signatures identify patients with sJIA at higher risk of flare during canakinumab tapering.
Study context
- Population
- Patients with systemic juvenile idiopathic arthritis (sJIA) in remission on canakinumab enrolled in a randomised withdrawal study71 with gene expression samples
- Participants
- 79 patients
- Comparison
- Successful vs unsuccessful canakinumab tapering
- Primary endpoint
- Serum and transcriptomic biomarkers predicting successful or unsuccessful canakinumab tapering
Methodological detailssecondary analysis of a randomised withdrawal study, Luminex serum biomarkers, whole-blood RNA sequencing (RNA-Seq), targeted 67-gene NanoString panel
- Secondary analysis of a randomised withdrawal study
- Luminex serum biomarkers
- Whole-blood RNA-Seq
- Targeted 67-gene NanoString panel
Primary result
As reported in the abstract
Predictors of tapering outcome
Composite 9-gene score discriminating successful from unsuccessful discontinuation, AUC
0.71
Further findings
Active vs inactive sJIA (RNA-Seq)
- Marked differences between active and inactive sJIA
Original publication
Predictive molecular signatures for successful tapering of canakinumab in systemic juvenile idiopathic arthritis. Ann Rheum Dis. Published 22 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →